|
|
Caredx Inc (NASDAQ: CDNA) |
|
Price: $50.8800
$1.02 
2.046%
|
| Day's High:
| $50.9900016784668
| Week Perf:
| 1.54 %
|
| Day's Low: |
$ 48.75 |
30 Day Perf: |
13.55 % |
| Volume (M): |
1,306,141 |
52 Wk High: |
$ 53.67 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$22.99 |
| Open: |
$49.65 |
52 Wk Low: |
$13.12 |
|
|
| Market Capitalization (Millions $) |
2,703 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
765 |
| Revenues (TTM) (Millions $) |
413 |
| Net Income (TTM) (Millions $) |
-8 |
| Cash Flow (TTM) (Millions $) |
-11 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
CardeDX Inc. is a commercial-stage precision medicine company that specializes in developing clinically actionable diagnostics to advance the field of transplant medicine. The company is based in Brisbane, California, and was founded in 2011. Its products and services are aimed at improving patient outcomes by providing accurate and reliable information about their transplant status.
Caredx's primary focus is on providing organ transplant patients with the latest diagnostic tools to ensure the best possible patient outcomes. The company's products and services are designed to help clinicians predict the likelihood of transplant rejection, monitor transplant patients for potential complications, and provide personalized treatment plans to prevent organ rejection.
Caredx's flagship product, the AlloSuree test, is a blood test that measures the fraction of donor-derived cell-free DNA circulating in a transplant recipient's bloodstream. The test provides clinicians with valuable information about the health of transplanted organs and helps to identify whether a patient is rejecting the transplant. The AlloSure test is the first and only commercially available test of its kind, and it is currently available in the United States and select international markets.
In addition to the AlloSure test, Caredx also offers a range of other diagnostic solutions for transplant patients, including the AlloMape test, which measures the expression of genes associated with organ rejection, and the AlloSeqe HLA genotyping test, which helps to identify the compatibility between a donor and recipient.
Caredx's services are primarily used by transplant centers, hospitals, and transplant specialists. The company has established partnerships with many leading academic medical centers and transplant organizations in the United States and internationally.
The company has a strong focus on research and development and has invested heavily in building a cutting-edge laboratory facility that allows for the development and testing of novel transplant diagnostics. In addition to developing new products and services, Caredx also works closely with transplant centers and transplant professionals to educate them about the latest advances in transplant diagnostic technology.
Caredx has received numerous awards and recognitions for its innovative products and services, including the 2016 Frost & Sullivan Technology Innovation Award and the 2018 Red Herring Top 100 North America Award.
Overall, Caredx is a leading player in the fast-growing field of precision medicine and is at the forefront of driving innovation and advancement in transplant diagnostics. With a strong commitment to research and development, the company is well-positioned to continue to grow and expand its product offerings and contribute to improving patient outcomes in the field of transplant medicine.
Company Address: 8000 Marina Boulevard, 4th Floor Zagreb 94005 City of Zagreb
Company Phone Number: 287-2300 Stock Exchange / Ticker: NASDAQ CDNA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Thu, Nov 6 2025 8:37 PM UTC
Revolutionizing Transplant Care: CareDx Unveils Groundbreaking Innovations and Research at ASN Kidney Week 2025 and World Transplant CongressIn the rapidly advancing field of transplant medicine, CareDx, Inc. (Nasdaq: CDNA) dubbed The Transplant Company has positioned itself as a leader in precision medicine, particularly for kidney transplant patients. At the recently held...
|
| Business Update
Published Tue, Oct 7 2025 9:27 AM UTC
Revolutionizing Transplant Medicine: CareDx s Breakthrough Innovations at the Forefront In the rapidly evolving world of precision medicine, CareDx, Inc. stands as a beacon of transformative potential and groundbreaking innovation, particularly in the field of organ transplantation. At the forefront of this evolution, CareDx has made significant advancements in both molecula...
|
| Business Update
Published Wed, Aug 6 2025 5:58 PM UTC
Utilizing Precision Medicine: CareDx s Innovative Studies Transforming Transplant OutcomesIn the evolving landscape of transplant medicine, precision tools are steadily emerging as pivotal in improving patient care and outcomes. Recent studies published by CareDx, Inc., a leader in precision medicine for transplant patients, underscore the significant impact of advanced dia...
|
| Business Update
Published Fri, Aug 1 2025 5:43 AM UTC
In the realm of transplant diagnostics, CareDx, Inc., headquartered in Brisbane, California, has emerged as a trailblazer, showcasing its commitment to precision medicine with impressive results at the 2025 World Transplant Congress (WTC). With over 40 abstracts and 16 oral presentations presented by independent research teams, CareDx has reinforced its reputation as a leade...
|
| Business Update
Published Fri, Feb 21 2025 5:44 AM UTC
In a significant advancement for transplant medicine, CareDx, Inc. (Nasdaq: CDNA), has unveiled promising findings regarding its AlloSeq cfDNA technology, demonstrating its high precision in detecting organ transplant rejection. Based in Brisbane, California, CareDx has positioned itself as a leader in precision medicine focused on developing clinically differentiated health...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.16 $ |
| Revenues (TTM) |
7.77 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.52 $
|
| Book Value |
5.9 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
539,634 |
| Net
Income per Employee (TTM) |
-10,708 |
| Receivable Turnover Ratio (TTM) |
8.16 |
| Inventory Turnover Ratio (TTM) |
2.34 |
| Asset Turnover Ratio (TTM) |
0.97 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.16 $
|
| Revenues (TTM) |
7.77 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.52 $
|
| Book Value |
5.9 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 96.56 % |
of total Revenue |
| Rest of World |
|
3.44 % |
of total Revenue |
| Testing services revenue |
|
77.65 % |
of total Revenue |
| Testing services revenue United States |
|
77.34 % |
of total Revenue |
| Testing services revenue Rest of World |
|
0.31 % |
of total Revenue |
| Product revenue |
|
8.79 % |
of total Revenue |
| Product revenue United States |
|
5.69 % |
of total Revenue |
| Product revenue Rest of World |
|
3.1 % |
of total Revenue |
| Patient and digital solutions revenue |
|
13.56 % |
of total Revenue |
| Patient and digital solutions revenue United States |
|
13.53 % |
of total Revenue |
| Patient and digital solutions revenue Rest of World |
|
0.03 % |
of total Revenue |
| Reportable Segment |
|
100 % |
of total Revenue |
| Reportable Testing services revenue |
|
77.65 % |
of total Revenue |
| Reportable Product revenue |
|
8.79 % |
of total Revenue |
| Reportable Patient and digital solutions revenue |
|
13.56 % |
of total Revenue |
| |
On January 13 2025 the Caredx Inc provided following guidance
nnCareDx Inc. Projects Impressive Financial Growth for Q4 and Full Year 2024nn
nnJanuary 13, 2025 – Brisbane, Californiann – CareDx, Inc. (Nasdaq: CDNA), a leading company in transplant diagnostics, has released preliminary unaudited financial results for the fourth quarter and the entire year ending December 31, 2024. The figures indicate a robust upward trend in revenue, affirming the company's strong market position.
For the fourth quarter of 2024, CareDx anticipates revenues between $85 million and $86 million, reflecting an impressive year-over-year growth of approximately 30%. This positive trajectory underscores the company's continued commitment to advancing transplant medicine....
|
|
|
0.61% 